The company is evaluating whether the drug, which targets cardiac complications, might be used treat patients with other ...

High-dose treatment with the therapy was found to cause a 3.3% overall improvement in left ventricular ejection fraction.

Shares of Cumberland Pharmaceuticals continued their eye-opening ascent Wednesday on heavy volume.

Cumberland Pharmaceuticals saw its shares pop Tuesday, finishing the trading day up 76 percent on heavy volume following ...